Initiator Pharma Valuation Multiples

Initiator Pharma Overview

About Initiator Pharma

Initiator Pharma AS is a Danish clinical-stage life science company developing drugs that target key unmet medical needs within the central and peripheral nervous system. Its pipeline consists of three clinical programs the clinical programs IP2018 and pudafensine for the treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the rare disease program IPTN2021 for Trigeminal Neuralgia, a severe neuropathic pain condition.

Founded

2016

HQ

Employees

2

Website

initiatorpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($3M)

EV

$20M

Valuation Multiples

Multiples.vc

Start free trial

Initiator Pharma Financials

Initiator Pharma reported last 12-month revenue of — and negative EBITDA of ($3M).

In the same LTM period, Initiator Pharma generated — in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).

Initiator Pharma P&L

In the most recent fiscal year, Initiator Pharma reported revenue of — and EBITDA of ($3M).

Initiator Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Initiator Pharma Stock Performance

Initiator Pharma has current market cap of $24M, and enterprise value of $20M.

Initiator Pharma's stock price is $0.35.

Initiator Pharma Valuation Multiples

Initiator Pharma trades at (6.3x) EV/EBITDA.

Initiator Pharma Financial Valuation Multiples

As of April 18, 2026, Initiator Pharma has market cap of $24M and EV of $20M.

Equity research analysts estimate Initiator Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Initiator Pharma has a P/E ratio of (9.4x).

Initiator Pharma Margins & Growth Rates

Initiator Pharma's revenue in the last fiscal year grew by —.

Initiator Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Initiator Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Initiator Pharma M&A Activity

Initiator Pharma acquired XXX companies to date.

Last acquisition by Initiator Pharma was on XXXXXXXX, XXXXX. Initiator Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Initiator Pharma Investment Activity

Initiator Pharma invested in XXX companies to date.

Initiator Pharma made its latest investment on XXXXXXXX, XXXXX. Initiator Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).